A Dose-Escalating, Single-Blind Study to Assess the Safety, Tolerability, and Pharmacokinetics of Multiple Doses of PRS-060 Administered by Oral Inhalation in Subjects With Mild Asthma

Trial Profile

A Dose-Escalating, Single-Blind Study to Assess the Safety, Tolerability, and Pharmacokinetics of Multiple Doses of PRS-060 Administered by Oral Inhalation in Subjects With Mild Asthma

Not yet recruiting
Phase of Trial: Phase I

Latest Information Update: 12 Jul 2018

At a glance

  • Drugs PRS 060 (Primary)
  • Indications Asthma
  • Focus Adverse reactions; Pharmacodynamics; Therapeutic Use
  • Sponsors AstraZeneca; Pieris Pharmaceuticals
  • Most Recent Events

    • 03 Jul 2018 Status changed from planning to not yet recruiting.
    • 17 Aug 2017 New trial record
    • 09 Aug 2017 According to a Pieris Pharmaceuticals media release, this trial is planned to conduct under a clinical trial notification to the Therapeutic Goods Administration in Australia.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top